Table 1.
Baseline Characteristics | CTD-ILD* (n = 148) | CHP† (n = 98) | U-ILD‡ (n = 159) | |||
---|---|---|---|---|---|---|
Center, n (%) | |
|
|
|||
University of California, Davis | 83 (56.1) |
60 (61.2) |
93 (58.5) |
|||
University of Chicago | 65 (43.9) |
38 (38.8) |
66 (41.5) |
|||
Age, mean ± SD | 61 ± 13.8 |
67.9 ± 9.7 |
68.5 ± 11.1 |
|||
Male sex, n (%) | 48 (32.4) |
49 (50) |
81 (50.9) |
|||
Race, n (%) | |
|
|
|||
White | 80 (54) |
71 (72.4) |
120 (75.4) |
|||
African American | 28 (18.9) |
4 (4.1) |
14 (8.8) |
|||
Hispanic | 26 (17.6) |
11 (11.2) |
6 (3.8) |
|||
Asian | 8 (5.4) |
3 (3.1) |
6 (3.8) |
|||
Other/unknown | 6 (4.1) |
9 (9.2) |
13 (8.2) |
|||
Ever smoker, n (%) | 69 (46.6) |
52 (53.1) |
90 (57) |
|||
Lung function | |
|
|
|||
FVC% predicted, mean ± SD | 67.2 ± 19 |
66.5 ± 20 |
69.1 ± 20 |
|||
DlCO% predicted, mean ± SD | 50.4 ± 18.9 |
55.1 ± 20.3 |
52.3 ± 21.1 |
|||
Immunosuppressive therapy, n (%)§ | 90 (60.8) |
42 (42.9) |
53 (33.3) |
|||
Immunosuppressive exposure months, median (IQR) | 24 (11–24) |
11.5 (5.5–24) |
12 (6.7–24) |
|||
GAP-ILD score, mean ± SD | 1.4 ± 1.3 |
1.8 ± 1.6 |
3.7 ± 1.6 |
|||
|
|
|
||||
Outcomes | |
|
|
|||
Death, n (%) | 17 (11.5) |
21 (21.4) |
37 (23.3) |
|||
Lung transplant, n (%) | 2 (1.4) |
2 (2.1) |
3 (1.9) |
|||
≥10% FVC decline, n (%) | 21 (14.2) |
32 (32.7) |
29 (18.2) |
|||
Follow-up months, median (IQR) | 12.7 (6.1–23.8) | 11 (6.8–19) | 11.2 (4.6–20.8) |
CTD-ILD* (n = 148) |
CHP† (n = 98) |
U-ILD‡ (n = 159) |
||||
---|---|---|---|---|---|---|
Preliminary biomarker analysis | Threshold | HR (95% CI) | Threshold | HR (95% CI) | Threshold | HR (95% CI) |
CXCL13 | 525 pg/ml | 4.78 (2.23–10.22)‖ | 140 pg/ml | 2.2 (1.22–3.96)‖ | 107 pg/ml | 3.17 (1.63–6.15)‖ |
CA-125 | 90 pg/ml | 3.31 (1.71–6.42)‖ | 46 pg/ml | 1.83 (1.01–3.29) | 117 pg/ml | 3.42 (1.66–7.07)‖ |
MMP7 | 7.9 ng/ml | 2.27 (1.0–5.17) | 6.5 ng/ml | 2.33 (1.27–4.28)‖ | 4.7 ng/ml | 2.26 (1.32–3.85)‖ |
YKL-40 | 80 ng/ml | 2.18 (1.12–4.24) | 58 ng/ml | 2.05 (1.14–3.71) | 30 ng/ml | 1.97 (0.96–4.03) |
SP-D | 34 ng/ml | 0.41 (0.15–1.16) | 25 ng/ml | 1.7 (0.89–3.25) | 21 ng/ml | 2.42 (1.27–4.59)‖ |
VCAM-1 | 2,116 ng/ml | 3.66 (1.6–8.4)‖ | 1,277 ng/ml | 4.12 (2.14–7.95)‖ | 1,887 ng/ml | 2.34 (1.0–5.49) |
Definition of abbreviations: CHP = chronic hypersensitivity pneumonitis; CI = confidence interval; CTD-ILD = connective tissue disease–associated interstitial lung disease; GAP-ILD = gender, age, physiology ILD score; HR = hazard ratio; IQR = interquartile range; U-ILD = unclassifiable interstitial lung disease.
n when values were missing (FVC = 140; DlCO = 135; GAP-ILD n = 140).
n when values were missing (DlCO = 90).
n when values were missing (ever smoker = 158; FVC = 156; DlCO = 144; GAP-ILD = 156).
Mycophenolate mofetil, azathioprine, cyclophosphamide, and/or rituximab.
Advanced for final analysis based on Cox model Wald P < 0.008, which adjusted for multiple testing.